keyword
https://read.qxmd.com/read/38703012/the-safety-of-trastuzumab-deruxtecan-ds-8201-with-a-focus-on-interstitial-lung-disease-and-or-pneumonitis-a-systematic-review-and-single-arm-meta-analysis
#1
JOURNAL ARTICLE
Ruijuan Li, Manqi Hua, Jiulong Li, Weihong Chen, Ling Xu, Huan Meng, Zhuo Zhang, Qianxin Liu, Yimin Cui, Qian Xiang
BACKGROUND: Previous studies involving risk-benefit analysis of trastuzumab deruxtecan (DS-8201) have indicated the benefit of this treatment, although it may increase the risk of interstitial lung disease (ILD) and/or pneumonitis in certain patients. This study aimed to assess the safety of DS-8201. METHODS: A search was done for relevant articles in four electronic databases: PubMed, Embase, the Cochrane Library, and ClinicalTrials.gov. All reports published up until November 2, 2022, were included, and study types were restricted to clinical trials; the last search was then updated to January 10, 2023...
May 4, 2024: Cancer
https://read.qxmd.com/read/38702973/a-multicenter-open-label-single-arm-trial-of-the-long-term-safety-of-empagliflozin-treatment-for-refractory-diabetes-mellitus-with-insulin-resistance-empire-02
#2
JOURNAL ARTICLE
Yushi Hirota, Yasumasa Kakei, Junta Imai, Hideki Katagiri, Ken Ebihara, Jun Wada, Junichi Suzuki, Tatsuhiko Urakami, Takashi Omori, Wataru Ogawa
AIMS/INTRODUCTION: Insulin resistance syndrome and lipoatrophic diabetes are rare conditions characterized by the development of treatment-refractory diabetes with severe insulin resistance. We recently conducted a 24 week, multicenter, single-arm trial (EMPIRE-01) that demonstrated a certain level of effectiveness and safety of empagliflozin for these conditions. To evaluate treatment safety over a longer period, we have now performed an additional 28 week trial (EMPIRE-02) that followed on from EMPIRE-01...
May 4, 2024: Journal of Diabetes Investigation
https://read.qxmd.com/read/38702918/pharmacokinetics-and-safety-of-atogepant-co-administered-with-quinidine-gluconate-in-healthy-participants-a-phase-1-open-label-drug-drug-interaction-study
#3
JOURNAL ARTICLE
Ramesh Boinpally, Lisa Borbridge, Veronica Wangsadipura
Atogepant, an oral calcitonin gene-related peptide receptor antagonist, is approved for the preventive treatment of migraine. Atogepant is a substrate of P-glycoprotein (P-gp), breast cancer resistance protein, organic anion transporting polypeptide transporters, and cytochrome P450 (CYP)3A4 and 2D6. Quinidine is a strong P-gp and CYP2D6 inhibitor. A phase 1 open-label study evaluated the effect of P-gp and CYP2D6 inhibition by quinidine on the pharmacokinetics of atogepant, and the safety and tolerability of atogepant and quinidine gluconate (QG) when co-administered and when given alone in 33 healthy adults...
May 3, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38702702/physiologic-oxygen-responses-to-smoking-opioids-an-observational-study-using-continuous-pulse-oximetry-at-overdose-prevention-services-in-british-columbia-canada
#4
JOURNAL ARTICLE
Jessica Moe, Jane A Buxton, Yueqiao Elle Wang, Tamara Chavez, Damian Feldman-Kiss, Charotte Marr, Roy A Purssell, Michael Otterstatter
BACKGROUND: In British Columbia, Canada, smoking is the most common modality of drug use among people who die of opioid toxicity. We aimed to assess oxygen saturation (SpO2 ) while people smoked opioids during a pilot study that introduced continuous pulse oximetry at overdose prevention services (OPS) sites. METHODS: This was an observational cohort study, using a participatory design. We implemented our monitoring protocol from March to August 2021 at four OPS...
May 3, 2024: Harm Reduction Journal
https://read.qxmd.com/read/38702350/feasibility-safety-efficacy-and-potential-scaling-up-of-sofosbuvir-based-hcv-treatment-in-central-and-west-africa-tac-anrs-12311-trial
#5
MULTICENTER STUDY
Karine Lacombe, Raoul Moh, Corine Chazallon, Maud Lemoine, Babacar Sylla, Fatoumata Fadiga, Jerôme Le Carrou, Fabienne Marcellin, Charles Kouanfack, Laura Ciaffi, Michelle Tagni Sartre, Magloire Biwole Sida, Alpha Diallo, Joel Gozlan, Moussa Seydi, Viviane Cissé, Christine Danel, Pierre Marie Girard, Thomas d'Aquin Toni, Albert Minga, Sylvie Boyer, Patrizia Carrieri, Alain Attia
Access to Hepatis C treatment in Sub-Saharan Africa is a clinical, public health and ethical concern. The multi-country open-label trial TAC ANRS 12311 allowed assessing the feasibility, safety, efficacy of a specific care model of HCV treatment and retreatment in patients with hepatitis C in Sub Saharan Africa. Between November 2015 and March 2017, with follow-up until mid 2019, treatment-naïve patients with HCV without decompensated cirrhosis or liver cancer were recruited to receive 12 week-treatment with either sofosbuvir + ribavirin (HCV genotype 2) or sofosbuvir + ledipasvir (genotype 1 or 4) and retreatment with sofosbuvir + velpatasvir + voxilaprevir in case of virological failure...
May 3, 2024: Scientific Reports
https://read.qxmd.com/read/38702260/application-of-the-academic-research-consortium-high-bleeding-risk-criteria-in-patients-treated-with-coronary-bioresorbable-polymer-everolimus-eluting-stents-insights-from-the-poem-trial
#6
JOURNAL ARTICLE
Antonio Popolo Rubbio, Luca Testa, Carlo A Pivato, Damiano Regazzoli, Raffaele Piccolo, Giovanni Esposito, Carmine Musto, Lorenzo Scalia, Andrea Pacchioni, Carlo Briguori, Luigi Lucisano, Leonardo De Luca, Federico Conrotto, Francesco Tartaglia, Alessia C Latini, Kamil Stankowski, Mauro Chiarito, Gennaro Sardella, Ciro Indolfi, Francesco Bedogni, Bernhard Reimers, Gianluigi Condorelli, Giulio G Stefanini
BACKGROUND: Previous studies have investigated a 1 to 6-month short dual antiplatelet therapy (S-DAPT) after percutaneous coronary intervention (PCI) with modern drug eluting-stents to reduce bleeding events. OBJECTIVES: To investigate cardiovascular outcomes in patients at high bleeding risk (HBR) according to the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria after PCI with the Synergy bioresorbable-polymer everolimus-eluting stents (EES)...
April 16, 2024: Cardiovascular Revascularization Medicine: Including Molecular Interventions
https://read.qxmd.com/read/38701967/predictors-of-systolic-function-recovery-after-atrial-fibrillation-ablation-in-heart-failure-patients
#7
JOURNAL ARTICLE
João Borges-Rosa, Pedro A Sousa, Natália António, Luís Elvas, Lino Gonçalves
INTRODUCTION AND OBJECTIVES: Atrial fibrillation (AF) and heart failure (HF) often coexist. AF catheter ablation improves left ventricular ejection fraction (LVEF), but its impact varies between patients. We aimed to identify predictors of LVEF improvement in HF patients with impaired LVEF undergoing AF ablation. METHODS: We conducted a retrospective single-center study in HF patients with LVEF <50% undergoing AF catheter ablation between May 2016 and May 2022...
May 1, 2024: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://read.qxmd.com/read/38701681/the-journey-of-the-asian-forensic-sciences-network-afsn-through-fifteen-years
#8
JOURNAL ARTICLE
Angeline Yap, Nellie Cheng
The Asian Forensic Sciences Network was formed in 2008 by a small group of six forensic institutes from six countries in Asia, with the vision to create a common platform for scientists in the region to come together to advance forensic science, raise quality standards, and foster collaboration. Since its inception, the network has experienced remarkable growth, now comprising 70 member institutes from 18 countries across Asia. An Annual Meeting & Symposium, hosted by a member institute each year, serves as a cornerstone event for the network...
April 24, 2024: Forensic Science International
https://read.qxmd.com/read/38701669/impact-of-neonatal-pain-and-opiate-administration-in-animal-models-a-meta-analysis-concerning-pain-threshold
#9
REVIEW
Philipp Steinbauer, Tamara Lisy, Francisco J Monje, Eva Chwala, Brigitte Wildner, Hannah Schned, Philipp Deindl, Angelika Berger, Vito Giordano, Monika Olischar
BACKGROUND AND AIM: Neonatal intensive care treatment, including frequently performed painful procedures and administration of analgesic drugs, can have different effects on the neurodevelopment. This systematic review and meta-analysis aimed to investigate the influence of pain, opiate administration, and pre-emptive opiate administration on pain threshold in animal studies in rodents, which had a brain development corresponding to preterm and term infants. METHODS: A systematic literature search of electronic data bases including CENTRAL (OVID), CINAHL (EBSCO), Embase...
April 26, 2024: Early Human Development
https://read.qxmd.com/read/38701407/abbv-319-a-cd19-targeting-glucocorticoid-receptor-modulator-antibody-drug-conjugate-therapy-for-b-cell-malignancies
#10
JOURNAL ARTICLE
Chewei Anderson Chang, Ethan Emberley, Aloma L D'Souza, Weilong Zhao, Cormac Cosgrove, Karen E Parrish, Diya Mitra, Elmer Payson, Anatol Oleksijew, Paul Ellis, Luis Rodriguez, Ryan Duggan, Cara Hrusch, Loren Lasko, Wissam Assaily, Pingping Zheng, Wei Liu, Axel Hernandez, Kimberley McCarthy, Zhaomei Zhang, Geunbae Rha, Zhensheng Cao, Yingchun Li, Olivia Perng, Jos Campbell, Gloria Zhang, Tyler Scott Curran, Milan Bruncko, Christopher C Marvin, Adrian D Hobson, Michael McPherson, Tamar Uziel, Marybeth A Pysz, Xi Zhao, Alexander Bankovich, Joel Hayflick, Michael McDevitt, Kevin J Freise, Susan Morgan-Lappe, James W Purcell
Glucocorticoids are key components of the current standard-of-care regimens (e.g., R-CHOP, EPOCH-R, Hyper-CVAD) for treatment of B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. CD19 displays restricted expression in normal B-cells and is up-regulated in B-cell malignancies. ABBV-319 is a CD19-targeting antibody-drug conjugate (ADC) engineered to reduce glucocorticoid-associated toxicities while possessing three distinct mechanisms of action (MOA) to increase therapeutic efficacy: (1) antibody-mediated delivery of glucocorticoid receptor modulator (GRM) payload to activate apoptosis, (2) inhibition of CD19 signaling, and (3) enhanced Fc-mediated effector function via afucosylation of the antibody backbone...
May 3, 2024: Blood
https://read.qxmd.com/read/38701317/application-of-intranasal-dexmedetomidine-in-magnetic-resonance-imaging-of-preterm-infants-the-ed50-efficacy-and-safety-analysis
#11
JOURNAL ARTICLE
Shengjun Wan, Wei Wu, Wenhao Bu
BACKGROUND: Infants undergoing magnetic resonance imaging (MRI) often require pharmacological sedation. Dexmedetomidine serves as a novel sedative agent that induces a unique unconsciousness similar to natural sleep, and therefore has currently been used as the first choice for sedation in infants and young children. OBJECTIVE: To determine the 50% effective dose (ED50) and 95% confidence interval (95%CI) of intranasal dexmedetomidine for MRI in preterm and term infants, and to observe the incidence of adverse events...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38701312/efficacy-and-safety-of-chinese-herbal-medicine-in-treating-postcholecystectomy-diarrhea-a-systematic-review-and-meta-analysis
#12
JOURNAL ARTICLE
Yan Sun, Yong Zhang, Zheng Wang, Quanda Liu, Juefei Mo
BACKGROUND: Postcholecystectomy diarrhea (PCD) is among the most distressing and well-known clinical complications of cholecystectomy. Despite various available treatment options, clinical outcomes are greatly limited by unclear pathophysiological mechanisms. Chinese herbal medicine (CHM) is widely used as a complementary and alternative therapy for the treatment of functional diarrhea. Thus, we conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of CHM for the treatment of PCD...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38701278/comparative-efficacy-and-safety-of-different-drugs-in-patients-with-systemic-juvenile-idiopathic-arthritis-a-systematic-review-and-network-meta-analysis
#13
COMPARATIVE STUDY
Baoquan Wang, Yushan Zhang, Zhenbiao Zhao, Juan Ping, Liming Zhou, Yining Wang, Yongzhou Zhang
BACKGROUND: The goal of this study was to estimate the relative efficacy and safety of different biological agents (infliximab, canakinumab, baricitinib, anakinra, adalimumab, tofacitinib, tocilizumab, and rilonacept) compared with placebo for systemic juvenile idiopathic arthritis (JIA) patients, through a network meta-analysis. METHODS: Pubmed, Embase, and Cochrane Library were searched from database inception to July 2023 for randomized controlled trials comparing different biological agents (infliximab, canakinumab, baricitinib, anakinra, adalimumab, tofacitinib, tocilizumab, and rilonacept) or placebo directly or indirectly in JIA...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38701263/efficacy-and-safety-of-transarterial-chemoembolization-combined-with-targeted-therapy-and-immunotherapy-versus-with-targeted-monotherapy-in-unresectable-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis
#14
JOURNAL ARTICLE
Jingwen Feng, Yi Zhao, Lin Zhai, Jingxu Zhou
BACKGROUND AND OBJECTIVE: The application of transarterial chemoembolization (TACE) in combination with targeted therapy and immunotherapy (TACE-T-I) for unresectable hepatocellular carcinoma (HCC) has gained increasing attention. However, there are variations in the efficacy and safety outcomes between TACE-T-I versus TACE combined with targeted drugs (TACE-T). This study aims to systematically evaluate the efficacy and safety of TACE-T-I versus TACE-T in unresectable HCC. METHODS: PubMed, Embase, Cochrane Library, and Web of Science databases were searched from inception to August 21, 2023, for comparative studies on TACE-T-I versus TACE-T for unresectable HCC...
May 3, 2024: Medicine (Baltimore)
https://read.qxmd.com/read/38701222/initial-clinical-experience-with-the-balloon-in-basket-pulsed-field-ablation-system-acute-results-of-the-volt-ce-mark-feasibility-study
#15
JOURNAL ARTICLE
Prashanthan Sanders, Stewart Healy, Mehrdad Emami, Emily Kotschet, Amber Miller, Jonathan M Kalman
BACKGROUND AND AIMS: Pulsed field ablation (PFA) for the treatment of atrial fibrillation (AF) potentially offers improved safety and procedural efficiencies compared to thermal ablation. Opportunities remain to improve effective circumferential lesion delivery, safety, and workflow of first generation PFA systems. Here we aim to evaluate the initial clinical experience with a balloon-in-basket, 3D integrated PFA system with a purpose-built form factor for pulmonary vein (PV) isolation...
May 3, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://read.qxmd.com/read/38701164/the-safety-of-modified-all-oral-shorter-tuberculosis-regimens-in-armenia
#16
JOURNAL ARTICLE
Hakob Atshemyan, Naira Khachatryan, Anush Khachatryan, Narine Mirzoyan
BACKGROUND: The implementation of modified, all-oral shorter regimens for treatment of rifampicin-resistant tuberculosis has started in Armenia since August 2020 under the conditions of operational research. OBJECTIVE: This study aims to evaluate the safety and effectiveness of shorter regimens. METHODS: We evaluated cumulative incidence rates of serious adverse events, adverse events of grade 3 and greater and events resulting in treatment modifications or suspension for 52 study participants...
May 3, 2024: International Journal of Risk & Safety in Medicine
https://read.qxmd.com/read/38701084/impact-and-cost-effectiveness-of-the-6-month-bpalm-regimen-for-rifampicin-resistant-tuberculosis-in-moldova-a-mathematical-modeling-analysis
#17
JOURNAL ARTICLE
Lyndon P James, Fayette Klaassen, Sedona Sweeney, Jennifer Furin, Molly F Franke, Reza Yaesoubi, Dumitru Chesov, Nelly Ciobanu, Alexandru Codreanu, Valeriu Crudu, Ted Cohen, Nicolas A Menzies
BACKGROUND: Emerging evidence suggests that shortened, simplified treatment regimens for rifampicin-resistant tuberculosis (RR-TB) can achieve comparable end-of-treatment (EOT) outcomes to longer regimens. We compared a 6-month regimen containing bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) to a standard of care strategy using a 9- or 18-month regimen depending on whether fluoroquinolone resistance (FQ-R) was detected on drug susceptibility testing (DST). METHODS AND FINDINGS: The primary objective was to determine whether 6 months of BPaLM is a cost-effective treatment strategy for RR-TB...
May 3, 2024: PLoS Medicine
https://read.qxmd.com/read/38701026/predictors-of-adherence-to-direct-oral-anticoagulants-after-cardiovascular-or-bleeding-events-in-medicare-advantage-plan-enrollees-with-atrial-fibrillation
#18
JOURNAL ARTICLE
Bilqees Fatima, Anjana Mohan, Issra Altaie, Susan Abughosh
BACKGROUND: Direct oral anticoagulants (DOACs) are recommended for patients with atrial fibrillation (AF) given their improved safety profile. Suboptimal adherence to DOACs remains a significant concern among individuals with AF. However, the extent of adherence to DOACs following a cardiovascular or bleeding event has not been fully evaluated. OBJECTIVE: To evaluate the pattern of adherence trajectories of DOACs after a cardiovascular or bleeding event and to investigate the sociodemographic and clinical predictors associated with each adherence trajectory by using claims-based data...
May 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38700923/mining-real-world-big-data-to-characterize-adverse-drug-reaction-quantitatively-mixed-methods-study
#19
JOURNAL ARTICLE
Qi-Xuan Yue, Ruo-Fan Ding, Wei-Hao Chen, Lv-Ying Wu, Ke Liu, Zhi-Liang Ji
BACKGROUND: Adverse drug reactions (ADRs), which are the phenotypic manifestations of clinical drug toxicity in humans, are a major concern in precision clinical medicine. A comprehensive evaluation of ADRs is helpful for unbiased supervision of marketed drugs and for discovering new drugs with high success rates. OBJECTIVE: In current practice, drug safety evaluation is often oversimplified to the occurrence or nonoccurrence of ADRs. Given the limitations of current qualitative methods, there is an urgent need for a quantitative evaluation model to improve pharmacovigilance and the accurate assessment of drug safety...
May 3, 2024: Journal of Medical Internet Research
https://read.qxmd.com/read/38700904/women-s-health-and-kidney-protective-medications
#20
JOURNAL ARTICLE
Mythri Shankar, Sehrish Ali, Silvi Shah
PURPOSE OF REVIEW: We discuss the sex-based differences in the pharmacokinetics and pharmacodynamics of kidney protective medications and their implications on women's health. RECENT FINDINGS: A critical examination of adverse drug reactions highlights the underrepresentation of women in clinical trials for kidney and cardiovascular protective drugs, such as SGLT2 inhibitors, ACE inhibitors, and endothelin receptor antagonists. This underscores the need for sex-specific analyses in clinical studies to accurately assess medication efficacy and safety...
May 6, 2024: Current Opinion in Nephrology and Hypertension
keyword
keyword
30704
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.